All In Biotech

Drug Trial Radar · NCT02682407

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease

Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

31

Actual

Start

Mar 10, 2016

Primary completion

Aug 25, 2020

Study completion Aug 25, 2020

Sponsor

Lead sponsor
Omeros CorporationIndustry
Sponsor type
Industry
First posted
Feb 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and tolerability of OMS721 (narsoplimab) in participants with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), Membranous Nephropathy (MN), and Complement Component 3 Glomerulopathy (C3G) including Dense Deposit Disease. The study will also evaluate Pharmacokinetics (PK), Pharmacodynamics (PD), anti-drug antibody response (ADA), and neutralizing antibodies (NAb) of narsoplimab when administered intravenously and when administered both intravenously and subcutaneously in participants of Asian descent with IgA Nephropathy.

Conditions

  • IgAN
  • LN
  • MN
  • C3G

Interventions

  • OMS721 (narsoplimab)Biological

    Biological: narsoplimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE).Time frame: up to 104 weeks
  2. Cohort 4: Proportion of IgAN Participants of Asian Descent With Treatment Related AEs.Time frame: 38 weeks
  3. Cohort 4: Change From Baseline in Serum and Urine Complement Component Levels.Time frame: 38 weeks

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Omeros Investigational Site

    Denver, Colorado

  • Omeros Investigational Site

    Augusta, Georgia

  • Omeros Investigational Site

    Lawrenceville, Georgia

  • Omeros Investigational Site

    Evergreen Park, Illinois

  • Omeros Investigational Site

    Voorhees Township, New Jersey

  • Omeros Investigational Site

    Flushing, New York

  • Omeros Investigational Site

    San Antonio, Texas

  • Omeros Investigational Site

    Milwaukee, Wisconsin

  • Omeros Investigational Site

    Chai Wan, Hong Kong

  • Omeros Investigational Site

    Hong Kong, Hong Kong

  • Omeros Investigational Site

    Kowloon, Hong Kong

  • Omeros Investigational Site

    Shatin, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.